Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis

Mehta, 2019, Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association, South Asian J. Cancer, 8, 250, 10.4103/sajc.sajc_373_18 Sahoo, 2011, Screening for EGFR mutations in lung cancer, a report from India, Lung Cancer, 73, 316, 10.1016/j.lungcan.2011.01.004 Hong, 2019, Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer, Oncol. Lett., 18, 3887 Yu, 2016, Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21, Chin. J. Cancer, 35, 30, 10.1186/s40880-016-0086-2 Uncommon EGFR Mutations. www.uncommonegfrmutations.com. Boehringer Ingelheim International GmbH. Last accessed on 26th March 2021. Edge, 2010, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann. Surg. Oncol., 17, 1471, 10.1245/s10434-010-0985-4 Amin, 2017, The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging, CA Cancer J. Clin., 67, 93, 10.3322/caac.21388 Mehta, 2020, Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape, Appl. Cancer Res., 40, 10.1186/s41241-020-00089-8 Zhang, 2020, Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups, Exp. Ther. Med., 19, 3513 Kate, 2019, Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis, Lung Cancer (Auckl), 10, 1 Singh, 2020, Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: a study from India, Lung Cancer, 149, 53, 10.1016/j.lungcan.2020.07.038 Syahruddin, 2018, Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients, Lung Cancer (Auckl), 9, 25 Lohinai, 2015, Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma, J. Thorac. Oncol., 10, 738, 10.1097/JTO.0000000000000492 Chen, 2016, Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China, Mol. Clin. Oncol., 4, 749, 10.3892/mco.2016.805 Yasuda, 2013, Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer, Sci. Transl. Med., 5, 10.1126/scitranslmed.3007205 Arcila, 2013, EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics, Mol. Cancer Ther., 12, 220, 10.1158/1535-7163.MCT-12-0620 Oxnard, 2013, Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions, J. Thorac. Oncol., 8, 179, 10.1097/JTO.0b013e3182779d18 Frega, 2017, Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations, Oncotarget, 8, 32626, 10.18632/oncotarget.15945 Wu, 2011, Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer, Clin. Cancer Res., 17, 3812, 10.1158/1078-0432.CCR-10-3408 Keam, 2014, Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer, Int. J. Clin. Oncol., 19, 594, 10.1007/s10147-013-0602-1 Hata, 2010, Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer, J. Thorac. Oncol., 5, 1524, 10.1097/JTO.0b013e3181e8b3c5 Hsieh, 2006, Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer, Lung Cancer, 53, 311, 10.1016/j.lungcan.2006.06.005 Kim, 2016, Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma, Cancer Biol. Ther., 17, 237, 10.1080/15384047.2016.1139235 Kobayashi, 2013, Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors, J. Thorac. Oncol., 8, 45, 10.1097/JTO.0b013e3182781e35 Kobayashi, 2015, EGFR Exon 18 Mutations in Lung Cancer: molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs, Clin. Cancer Res., 21, 5305, 10.1158/1078-0432.CCR-15-1046 Takano, 2005, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer, J. Clin. Oncol., 23, 6829, 10.1200/JCO.2005.01.0793 Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J. Natl. Cancer Inst., 97, 643, 10.1093/jnci/dji112 Shan, 2015, Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients, Lung Cancer, 89, 337, 10.1016/j.lungcan.2015.06.008 Sasaki H., Shimizu S., Okuda K., et al. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer 2009;64:295–300. Fiala, 2016, Epidermal growth factor receptor gene amplification in patients with advanced-stage NSCLC, Anticancer Res., 36, 455 Ji, 2006, Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors, Proc. Natl. Acad. Sci. U. S. A., 103, 7817, 10.1073/pnas.0510284103 Yang, 2015, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6, Lancet Oncol., 16, 830, 10.1016/S1470-2045(15)00026-1 Welcome trust sanger institute: catalogue of somatic mutations in cancer. Available from http://www.Sanger.Ac.UK/genetics/cgp/cosmic. Chung, 2012, Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR, Clin. Cancer Res., 18, 3470, 10.1158/1078-0432.CCR-11-2353